Document is current
Any future updates will be listed below
-
Authors
Kumar, Madhukar
Abbass, Nadia J.
Russell, Matthew W.
Das, Nikhil
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
Case Western Reserve University School of Medicine | Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University (UL1TR002548, UL1TR002548, UL1TR002548, UL1TR002548, UL1TR002548, UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A), P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 14 August 2024
Revised: 3 March 2025
Accepted: 24 April 2025
First Online: 10 May 2025
Competing interests
: KET reports Alimera (consultant), Apellis (consultant), Bausch and Lomb (consultant), Eyepoint (consultant), Genentech (consultant, speaker’s bureau), Iveric Bio (speaker’s bureau), Regeneron (research), Regenxbio (research), Zeiss (research). RPS reports personal fees from Eyepoint, Ocular Therapeutix, Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, Apellis. All other authors report no disclosures.
